Sodium/iodide symporter (NIS)-mediated iodide uptake in thyroid follicular cells is the basis of clinical utilization of radioiodines. The cloning of the NIS gene enabled applications of NIS as a reporter gene in both preclinical and translational research. Non-invasive NIS imaging with radioactive iodides and iodide analogs has gained much interest in recent years for evaluation of thyroid cancer and NIS reporter expression. Although radioiodines and [ 
Introduction
Iodine is an essential element in thyroid physiology and the accumulation of iodine in the thyroid was found to be a critical step for the synthesis of thyroid hormones as early as 1915. For over a half century, radioiodines have been successfully used in diagnosis and therapy of thyroid disorders such as hyperthyroidism and thyroid cancer [1] [2] [3] . Despite advancement in newer targeted therapies, the clinical utilization of radioiodines remains robust in therapeutic management of thyroid function and monitoring outcomes of treatment [4] [5] [6] [7] [8] .
The mechanism of iodide uptake was not fully elucidated until the NIS gene was cloned in 1996 [9, 10] . This work tremendously improved the understanding of thyroid physiology and enabled new approaches for molecular imaging and treatment [4, 5, [11] [12] [13] [14] . Due to the broad availability of SPECT and PET scanners and iodide radiopharmaceuticals ([ 123/124/131 I]I -and [ 99m Tc]TcO 4 -), NIS has been developed as an imaging reporter gene with great promise for clinical translation [15] [16] [17] [18] . Despite the success of [ 99m Tc]TcO 4 -and radioiodides for use in NIS
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International Publisher imaging, there are certain limitations in availability and physical properties of these radioisotopes. These limitations have been largely addressed by the recent development of [ 18 F]TFB for NIS imaging using PET [19] . Initial clinical trials of [ 18 F]TFB have been completed in healthy human subject [20] and thyroid cancer patients [21, 22] . This review focuses on the development of [ 18 F]TFB and closely related compounds as iodide analogs for PET imaging of NIS expression in tissues.
Noninvasive imaging of NIS
There are a few techniques available for NIS expression monitoring. Currently, SPECT and PET offer the best sensitivity in NIS imaging [23, 24] . Moreover, the integration of SPECT or PET and computed tomography (CT) allows the combination of functional data with detailed anatomical images to generate more accurate localization and quantitative estimated radioactivity concentrations in live subjects [25, 26] . Several iodide radionuclides have been used for noninvasive imaging of NIS expression using SPECT and PET modalities ( Table 1) . 
SPECT imaging of NIS
SPECT is a useful noninvasive imaging technique. Three-dimensional images are obtained by detecting photons emitted from a radionuclide [27] , e.g., technetium-99m or iodine-123/125/131. Technetium-99m has a half-life of 6 h and high abundance of photon emission with desirable energy (98.6%, 141 keV) for medical diagnostic imaging [28, 29] . The anion [ 99m Tc]TcO 4 -is a good transport substrate for NIS and therefore is useful for NIS imaging using SPECT [15] . Technetium-99m is the daughter product of molybdenum-99 [30] , and is usually eluted from a generator. However, the global shortage of technetium-99m has bothered the medical imaging field in the last two decades due to the fragile supply chain of molybdenum-99 [31] [32] [33] . Iodine-123 is the most suitable radioiodine for SPECT imaging of NIS [34] [35] [36] . Iodine-123 has a half-life of 13.3 h and 83.3% emitted photon with predominant energy of 159 keV, which is close to technetium-99m [37] . Iodine-123 provides higher sensitivity and imaging quality compared to iodine-125/131. Iodine-125 has limited use in SPECT because of its rather low photon energy (35 keV) and undesirable long half-life (59 d) [38] . [ 131 I]I -can be used as both diagnostic and therapeutic agent [39] [40] [41] . Iodine-131 has a half-life of 8 days with two step emission of beta particles (89%, 606 keV) and photon emission (81%, 364 keV), which is too high for optimal imaging with poor quality. The long half-lives of radioiodine in diagnostic imaging resulted in extra exposure for both patient and staff. Meanwhile, all the radioiodides [ 123/125/131 I]I -have limitations of availability due to the requirement of specialized production systems [42] , which are only available in limited sites.
PET imaging of NIS

PET imaging of NIS using [ 124 I]iodide
PET is a highly sensitive noninvasive imaging technique that utilizes positron-emitting radiopharmaceuticals. Three-dimensional images are reconstructed from detected pairs of photons (511 keV) emitted upon annihilation of positrons with electrons in tissue. Currently, PET imaging offers the highest imaging sensitivity for detecting low levels of reporter gene expression. Iodine-124 is a positron-emitting radionuclide [43] that has been used for NIS imaging using PET and has the advantages of superior quantitation and imaging sensitivity of PET relative to SPECT [44] . However, iodine-124 suffers several drawbacks [45] : 1) its 4.2 d half-life and low positron yield are undesirable for diagnostic imaging as these result in high radiation exposures; 2) its high energy single photon emissions (0.6-1.7 MeV) can degrade image quality; and 3) its high positron emission energy results in >6 mm maximum travel in tissue before annihilation [15] , which degrades imaging resolution.
[ 18 F]TFB provides a new approach for NIS imaging with PET
Fluorine-18 is the radionuclide of choice for clinical PET studies [46] . It has a high positron emission yield (98%) and relatively low energy (0.64 MeV), providing a limited maximum distance travelled in tissue before annihilation, which gives excellent resolution. Its half-life of 109.8 min is compatible with typical imaging period, resulting in acceptable radiation exposure levels. Moreover, due to the widespread use of [ 18 [50] . Meanwhile, the hexafluorophosphate (PF 6 -) ion has been shown the highest known affinity as an inhibitor for NIS transport [50, 51] . More details about the radiochemistry and biological evaluation of these newer fluorine-18 labeled probes will be described in the following sections. (Figure 2 ). [ 18 F]TFB was conveniently purified with a disposable silver ion-loaded cation exchange cartridge and two alumina N cartridges, and the quality control was performed by thin-layer chromatography and anion HPLC. Using this simple and practical production method, the molar activity of [ 18 F]TFB reported by Jauregui-Osoro was up to 1 GBq/μmol with a starting activity of 12-18 GBq, which is moderate with respect to molar activities commonly required for receptor-binding radiopharmaceuticals [52] . Also, the 10% radiochemical yield was rather low. 
Synthesis of fluorine
Preclinical imaging studies
Preclinical PET imaging in mice
Normal mice
Using isotope-exchange labeled [ 18 F]TFB, Jauregui-Osoro et al. [19] reported in vitro uptake in NIS-expressing FRTL-5 rat thyroid cell lines and PET imaging in BALD/c mice (Figure 4) 3 -could greatly avoid the saturable effect in NIS imaging, a moderate amount of bone uptake was also observed, indicating in vivo defluorination of the probe. (Figure 6 ). In the PET images, high contrast was observed in the uptake of NIS positive tumor over that of NIS negative tumor.
NIS gene reporter imaging in mice
[ 18 F]TFB uptake was found to decrease in iodide-accumulating tissues in mice as a function of molar activity (Figure 6C-E 
[ 18 F]TFB imaging for cell tracking in mice
NIS has been used as a reporter gene in cell tracking studies, which was successfully monitored by iodine-124 PET imaging [59] . Based on their previous work, Lee et al. [60] explored [ 18 F]TFB PET imaging in the tracking of dendritic cell (DC) migration by transfection of murine DC cell lines with hNIS and effluc genes (the latter were monitored by bioluminescence imaging). To monitor the migration of DC cells toward draining popliteal lymph nodes (DPLNs), parental cells were subcutaneously injected into footpads. Immigration of DCs to lymph nodes was successfully monitored using [ 18 F]TFB PET/CT at day 2 imaging and the results were consistent with bioluminescence imaging (Figure 9 ). These data supported the feasibility of using [ 18 F]TFB for hNIS reporter gene imaging to track the migration of DCs to lymph nodes. In this study, 1×10 7 cells were contained in the injectate administered to the footpads. Thus, this study begins to provide data on the limits of sensitivity of the [ 18 F]TFB in the application for reporter gene imaging. The ability to monitor NIS expression by PET is likely dependent on a number of factors, including tissue perfusion, density of NIS-expressing cells in target tissue, expression levels of NIS within the cells, molar activity of radiotracer, presence of competing substrates, injected dose, uptake of radiotracer in surrounding background tissues and imaging characteristics of the PET scanner.
Preclinical imaging studies using cancer cells engineered to express reporter genes can provide valuable information on the regional and temporal aspects of tumor metastasis. Diocou et al. [61] recently reported the use of [ 18 F]TFB for metastasis detection in a NIS-expressing orthotopic xenograft breast cancer model (Figure 10) 
Preclinical [ 18 F]TFB PET in a pig model
Large animal model investigations with [ 18 F]TFB may take advantage of the accurate quantitation afforded from measured attenuation correction. Hickey et al. [62] reported on the application of 
[ 18 F]TFB PET in non-human primates
Marti-Climent et al. [63] reported the first PET evaluation of [ 18 F]TFB in non-human primates. In this study, whole-body PET imaging was done in two male Macaca fascicularis monkeys. [ 18 F]TFB PET images (Figure 12) clearly delineated the thyroid with excellent resolution. Following a rapid vascular clearance phase, a great majority of the radiotracer was localized in NIS-expressing organs (thyroid, 
Clinical evaluation of [ 18 F]TFB
[ 18 F]TFB PET imaging in healthy human volunteers
Given the excellent properties of [ 18 F]TFB as a NIS imaging radiotracer evidenced in the preclinical studies, further evaluation of [ 18 F]TFB in humans has been initiated. Jiang et al. [20] reported the first [ 18 F]TFB evaluation in 8 healthy human subjects (4 male, 4 female) utilizing the BF 3 synthesis method ( Figure 13 ). Molar activities of [ 18 F]TFB at injection were approximately 3 GBq/μmol. Safety, pharmacokinetics, biodistribution, stability and radiation dosimetry of [ 18 F]TFB were assessed by dynamic and whole-body static PET/CT scans over 4 h after intravenous administration. Overall, [ 18 F]TFB administration was well tolerated with no significant findings on vital signs and no clinically meaningful changes in clinical laboratory assays. Uptake of [ 18 F]TFB was observed in well-known NIS-expressing tissues (thyroid, salivary glands and stomach). The left-ventricular blood pool time-activity curves early after injection showed a multiphasic blood clearance of radiotracer with two rapid clearance phases over the first 20 min, followed by a slower clearance phase. HPLC analysis showed excellent tracer in vivo stability in the blood and urine over the length of 4 h study. High uptake in thyroid supports further evaluation of [ 18 F]TFB in thyroid related disorders. Low background uptake in liver, skeletal muscle, cerebral cortex and other low NIS-expressing tissues will allow evaluation of NIS gene expression in these tissues, whereas the few tissues with high uptake (thyroid, salivary glands and stomach) will be disadvantaged for assessing NIS reporter expression.
[ 18 F]TFB PET imaging in thyroid cancer patients
O'Doherty et al. [21] reported the first [ 18 F]TFB PET imaging results in thyroid cancer patients ( Figure  14) . For this study, [ 18 F]TFB was administrated with molar activities of 2.6±1.4 GBq/μmol at time of injection. Dynamic whole-body imaging in five patients showed the rapid clearance of radiotracer from the circulation with excellent target-to-background ratios in NIS-expressing tissues (thyroid, salivary glands, stomach) within 30-45 min post-injection. Thyroid tumor nodules (13-114 mm maximum diameter) were found to be photopenic against the higher background [ 18 F]TFB uptake in normal thyroid, consistent with lower hNIS expression in differentiated thyroid cancer (DTC) relative to normal thyroid. No significant changes in vital signs or electrocardiograms were observed. Radiation dosimetry estimates were found to be similar as many other fluorine-18 labeled radiotracers. More recently, Samnick et al. [22] [65] . These phase 2 trials are necessary to support future regulatory submissions on the use of NIS reporter gene in virotherapy.
With regard to the dependence of [ 18 F]TFB imaging characteristics on molar activity, more data is required in humans to understand this relationship. As noted, the previously discussed studies used preparations that resulted in human administration of [ 18 F]TFB at similar molar activities of approximately 3 GBq/μmol [20, 21] . This level of molar activity is achievable with the isotope-exchange method or BF 3 -based radiosynthesis methods, although in our hands, we are able to achieve ~2-fold higher radiochemical yields and ~5-fold higher molar activities with the BF 3 -based method, which may allow for longer delays between end of synthesis and radiotracer administration. Obviously, further work is required to define recommended minimum molar activity levels to avoid saturation effects at NIS transporters and maintain target-to-background characteristics.
Conclusion and perspectives
NIS has been extensively evaluated as a target for therapy and reporter gene in the last two decades after the cloning of the NIS gene. 
